[
  {
    "ts": null,
    "headline": "Eli Lilly Falls After Novo Nordisk Price Cuts",
    "summary": "Novo plans up to 50% reductions on Wegovy and Ozempic list prices starting in 2027.",
    "url": "https://finnhub.io/api/news?id=32b77c6dabbd58350ee54c8358e18f68d3555c4166f55a837b92614ba0d1946e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771965332,
      "headline": "Eli Lilly Falls After Novo Nordisk Price Cuts",
      "id": 139201552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo plans up to 50% reductions on Wegovy and Ozempic list prices starting in 2027.",
      "url": "https://finnhub.io/api/news?id=32b77c6dabbd58350ee54c8358e18f68d3555c4166f55a837b92614ba0d1946e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Warns Sales Will Drop as Zepbound Overtakes Wegovy",
    "summary": "Lilly's Zepbound surpasses Wegovy in dollar sales, while pricing cuts and copycats pressure Novo's growth outlook.",
    "url": "https://finnhub.io/api/news?id=de07d5f7784d505785d6c5d8362fd6060e1b1fe39acb2ffc85bbd581ba6e2ebf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771965176,
      "headline": "Novo Warns Sales Will Drop as Zepbound Overtakes Wegovy",
      "id": 139201553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's Zepbound surpasses Wegovy in dollar sales, while pricing cuts and copycats pressure Novo's growth outlook.",
      "url": "https://finnhub.io/api/news?id=de07d5f7784d505785d6c5d8362fd6060e1b1fe39acb2ffc85bbd581ba6e2ebf"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Unveils Up to 50% US Price Cut for Wegovy, Ozempic",
    "summary": "Drugmaker sets $675 monthly list price starting Jan. 1, as shares fall 2.8% and stock slides 19% after CagriSema results.",
    "url": "https://finnhub.io/api/news?id=2ec0836b557b00d87bf31420f185f824967ba0df41f13759685c87edb012faaf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771962518,
      "headline": "Novo Nordisk Unveils Up to 50% US Price Cut for Wegovy, Ozempic",
      "id": 139201554,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drugmaker sets $675 monthly list price starting Jan. 1, as shares fall 2.8% and stock slides 19% after CagriSema results.",
      "url": "https://finnhub.io/api/news?id=2ec0836b557b00d87bf31420f185f824967ba0df41f13759685c87edb012faaf"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Drops After Novo Nordisk Unleashes Massive GLP-1 Price Cuts",
    "summary": "Novo Nordisk Triggers Market Jolt With Aggressive Drug Price Reduction Plan",
    "url": "https://finnhub.io/api/news?id=5abf9c3a57ef5e098f2b1f11a103c300daa838a17feebe21f55e29242c0ac5a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771962442,
      "headline": "Eli Lilly Drops After Novo Nordisk Unleashes Massive GLP-1 Price Cuts",
      "id": 139201555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk Triggers Market Jolt With Aggressive Drug Price Reduction Plan",
      "url": "https://finnhub.io/api/news?id=5abf9c3a57ef5e098f2b1f11a103c300daa838a17feebe21f55e29242c0ac5a2"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Novo Nordisk, Chinese pharma and biotech firms and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=dfa10cbada6d9cfda2ae8df0a054c4a85b69c057bf9ab8162a5c3fa5cf8cb8ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771953960,
      "headline": "Health Care Roundup: Market Talk",
      "id": 139200859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Find insight on Novo Nordisk, Chinese pharma and biotech firms and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=dfa10cbada6d9cfda2ae8df0a054c4a85b69c057bf9ab8162a5c3fa5cf8cb8ea"
    }
  },
  {
    "ts": null,
    "headline": "Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026",
    "summary": "LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.",
    "url": "https://finnhub.io/api/news?id=1ee4d498bdd8706f6b676602fa87d3e2aeab43cb2482a22758a08b3093bdc6c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771952400,
      "headline": "Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026",
      "id": 139200860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.",
      "url": "https://finnhub.io/api/news?id=1ee4d498bdd8706f6b676602fa87d3e2aeab43cb2482a22758a08b3093bdc6c4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk, Eli Lilly Stocks Drop on Wegovy Maker's Price-Cut Plan",
    "summary": "Novo Nordisk shares fell following the news that the drug maker plans to slash its U.S. list prices for its popular obesity and diabetes treatments by up to half next year.    The Wegovy and Ozempic maker's American depositary receipts (NVO) fell more than 2% in morning trade, extending a multiday slide.",
    "url": "https://finnhub.io/api/news?id=0c14afe5e486cb42d6ce151c352ffc9e31f238308db8554d67209dad326f8198",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771947837,
      "headline": "Novo Nordisk, Eli Lilly Stocks Drop on Wegovy Maker's Price-Cut Plan",
      "id": 139198788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk shares fell following the news that the drug maker plans to slash its U.S. list prices for its popular obesity and diabetes treatments by up to half next year.    The Wegovy and Ozempic maker's American depositary receipts (NVO) fell more than 2% in morning trade, extending a multiday slide.",
      "url": "https://finnhub.io/api/news?id=0c14afe5e486cb42d6ce151c352ffc9e31f238308db8554d67209dad326f8198"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss",
    "summary": "The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.",
    "url": "https://finnhub.io/api/news?id=4bb95851ac7be69dc961ad7852a00afb2ea98ac31d19e2d50970f2eb5f1c9626",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771947494,
      "headline": "Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss",
      "id": 139212447,
      "image": "https://image.cnbcfm.com/api/v1/image/108261299-1770641604537-108261299-17702146372026-02-04t141011z_1036041844_rc20fjavm80v_rtrmadp_0_novo-nordisk-results.jpg?v=1770641619&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound. ",
      "url": "https://finnhub.io/api/news?id=4bb95851ac7be69dc961ad7852a00afb2ea98ac31d19e2d50970f2eb5f1c9626"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk to slash Wegovy and Ozempic prices starting in 2027",
    "summary": "Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.",
    "url": "https://finnhub.io/api/news?id=4c1d7c403452350c1407b3b2fa24ae70d18ed634c28bbcce62234e37115855c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771945696,
      "headline": "Novo Nordisk to slash Wegovy and Ozempic prices starting in 2027",
      "id": 139197287,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.",
      "url": "https://finnhub.io/api/news?id=4c1d7c403452350c1407b3b2fa24ae70d18ed634c28bbcce62234e37115855c8"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading",
    "summary": "Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading",
    "url": "https://finnhub.io/api/news?id=500cb92491f0171fe790145e1e402dc5be89c1e147d19d0260fa426412f9c929",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771943438,
      "headline": "Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading",
      "id": 139200710,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=500cb92491f0171fe790145e1e402dc5be89c1e147d19d0260fa426412f9c929"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%",
    "summary": "Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%",
    "url": "https://finnhub.io/api/news?id=d0784dfc2fea7ce18ccac0f706c09b4c2166f09fb8798e9880caa8c94b8a26ee",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771942740,
      "headline": "Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%",
      "id": 139211390,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%",
      "url": "https://finnhub.io/api/news?id=d0784dfc2fea7ce18ccac0f706c09b4c2166f09fb8798e9880caa8c94b8a26ee"
    }
  },
  {
    "ts": null,
    "headline": "Stock in Rivals Novo Nordisk and Eli Lilly Slips",
    "summary": "Novo Nordisk (NVO), (DK:NOVO.B) plans to slash U.S. list prices for its popular Wegovy and Ozempic by up to half starting next year. The Danish drugmaker a day earlier disclosed that its next-generation obesity treatment failed to beat Eli Lilly's Zepbound in a head-to-head study, though, and its Danish-listed shares fell around 2.",
    "url": "https://finnhub.io/api/news?id=9674faeaa038a46507e3095712cc9a38328f17b4b17974c8b3ee8e33f24ad2dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771942736,
      "headline": "Stock in Rivals Novo Nordisk and Eli Lilly Slips",
      "id": 139197288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO), (DK:NOVO.B) plans to slash U.S. list prices for its popular Wegovy and Ozempic by up to half starting next year. The Danish drugmaker a day earlier disclosed that its next-generation obesity treatment failed to beat Eli Lilly's Zepbound in a head-to-head study, though, and its Danish-listed shares fell around 2.",
      "url": "https://finnhub.io/api/news?id=9674faeaa038a46507e3095712cc9a38328f17b4b17974c8b3ee8e33f24ad2dc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound",
    "summary": "The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic strategy, with analysts slashing price targets and two major banks walking away from bullish positions Novo Nordisk's (NYSE:NVO) last best hope for life after semaglutide...",
    "url": "https://finnhub.io/api/news?id=2d1d1220f1b4d8ca7fd5ae28aa39267f28b77f224347fa053746fb3ca3b1eca4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771942504,
      "headline": "Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound",
      "id": 139197289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic strategy, with analysts slashing price targets and two major banks walking away from bullish positions Novo Nordisk's (NYSE:NVO) last best hope for life after semaglutide...",
      "url": "https://finnhub.io/api/news?id=2d1d1220f1b4d8ca7fd5ae28aa39267f28b77f224347fa053746fb3ca3b1eca4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk halves US price of weight-loss drug",
    "summary": "Novo Nordisk is halving the US list price of its most popular weight-loss drug as the Danish drugmaker struggles to compete with rival Eli Lilly...",
    "url": "https://finnhub.io/api/news?id=39c2269b5abe8df818683e6cc4b7a18b72a32d0c7d07df471d2cf10aecda2c2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771941742,
      "headline": "Novo Nordisk halves US price of weight-loss drug",
      "id": 139197290,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk is halving the US list price of its most popular weight-loss drug as the Danish drugmaker struggles to compete with rival Eli Lilly...",
      "url": "https://finnhub.io/api/news?id=39c2269b5abe8df818683e6cc4b7a18b72a32d0c7d07df471d2cf10aecda2c2c"
    }
  },
  {
    "ts": null,
    "headline": "IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?",
    "summary": "With Amtagvi sales surging but shares down 46%, can Iovance's growth runway outshine Rigel's strong 2025 rally?",
    "url": "https://finnhub.io/api/news?id=12cda64c8db5988c7daef8c81854ac9ae906846773d4efed1aaa47fde521dde7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771941720,
      "headline": "IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?",
      "id": 139197291,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With Amtagvi sales surging but shares down 46%, can Iovance's growth runway outshine Rigel's strong 2025 rally?",
      "url": "https://finnhub.io/api/news?id=12cda64c8db5988c7daef8c81854ac9ae906846773d4efed1aaa47fde521dde7"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Like A Coiled Spring, Often Harbinger of A Big Move; World's Smartest Banker Warns",
    "summary": "Big Move Ahead",
    "url": "https://finnhub.io/api/news?id=c8a1a22656dd844f864f9563d56f4a82c3e1c9e710ef1ee926c38997a605fb1c",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771939809,
      "headline": "Stock Market Like A Coiled Spring, Often Harbinger of A Big Move; World's Smartest Banker Warns",
      "id": 139207416,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "\n\n\n\nBig Move Ahead\n\n\n",
      "url": "https://finnhub.io/api/news?id=c8a1a22656dd844f864f9563d56f4a82c3e1c9e710ef1ee926c38997a605fb1c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Cutting Ozempic and Wegovy Prices. The Stock Is Still Slumping.",
    "summary": "The Danish drugmaker released a promising update about a trial in China, but that didn’t end a rough run for shares.",
    "url": "https://finnhub.io/api/news?id=d70cd7b0820e6f507e864296a678d83bc1eb79cf6c827fd528f382bc183ec965",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771939260,
      "headline": "Novo Nordisk Is Cutting Ozempic and Wegovy Prices. The Stock Is Still Slumping.",
      "id": 139197292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Danish drugmaker released a promising update about a trial in China, but that didn’t end a rough run for shares.",
      "url": "https://finnhub.io/api/news?id=d70cd7b0820e6f507e864296a678d83bc1eb79cf6c827fd528f382bc183ec965"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly falls 2% on Novo Nordisk price cut plans",
    "summary": "Investing.com -- Eli Lilly (NYSE:LLY) shares fell 2.2% Tuesday morning following a Wall Street Journal report that rival Novo Nordisk plans to slash U.S. list prices for its weight-loss and diabetes drugs Ozempic and Wegovy by up to 50%. Novo Nordisk shares were lower by 3%.",
    "url": "https://finnhub.io/api/news?id=99aa6d267d470cbd04ea32ea7554611142fe64d406c5dd8d29cf01f2c68ae7f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771938827,
      "headline": "Eli Lilly falls 2% on Novo Nordisk price cut plans",
      "id": 139194398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Eli Lilly (NYSE:LLY) shares fell 2.2% Tuesday morning following a Wall Street Journal report that rival Novo Nordisk plans to slash U.S. list prices for its weight-loss and diabetes drugs Ozempic and Wegovy by up to 50%. Novo Nordisk shares were lower by 3%.",
      "url": "https://finnhub.io/api/news?id=99aa6d267d470cbd04ea32ea7554611142fe64d406c5dd8d29cf01f2c68ae7f3"
    }
  },
  {
    "ts": null,
    "headline": "Novo to cut Ozempic and Wegovy prices amid intense competition",
    "summary": "Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.",
    "url": "https://finnhub.io/api/news?id=f9eb6e2bf021e7a697f7ee4b93c1027b8339f5c5cef92ff14c69c9869f728a70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771938082,
      "headline": "Novo to cut Ozempic and Wegovy prices amid intense competition",
      "id": 139194399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.",
      "url": "https://finnhub.io/api/news?id=f9eb6e2bf021e7a697f7ee4b93c1027b8339f5c5cef92ff14c69c9869f728a70"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Tuesday: FedEx, Home Depot, Apple",
    "summary": "? FedEx (FDX): The parcel-delivery company filed a lawsuit seeking a full refund plus interest for what it paid in levies stemming from President Trump’s tariffs enacted last year. ↘️ Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://finnhub.io/api/news?id=75c32aa23b709e522b5aa55e28526b721595fb45c631ccd57a617d12631e1de5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771932400,
      "headline": "Stocks to Watch Tuesday: FedEx, Home Depot, Apple",
      "id": 139193199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "? FedEx (FDX): The parcel-delivery company filed a lawsuit seeking a full refund plus interest for what it paid in levies stemming from President Trump’s tariffs enacted last year. ↘️ Novo Nordisk (NVO), (DK:NOVO.",
      "url": "https://finnhub.io/api/news?id=75c32aa23b709e522b5aa55e28526b721595fb45c631ccd57a617d12631e1de5"
    }
  },
  {
    "ts": null,
    "headline": "UK's MHRA Approves Imlunestrant Tosylate (Inluriyo) For Treatment For Breast Cancer",
    "summary": "https://www.gov.uk/government/news/mhra-approves-imlunestrant-tosylate-inluryo-a-new-treatment-for-breast-cancer",
    "url": "https://finnhub.io/api/news?id=fedecfa5364cb25e68721b9b014ff56edf68dd64fca3dd8cfa9cb0e7734ab8e0",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771936070,
      "headline": "UK's MHRA Approves Imlunestrant Tosylate (Inluriyo) For Treatment For Breast Cancer",
      "id": 139208608,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "https://www.gov.uk/government/news/mhra-approves-imlunestrant-tosylate-inluryo-a-new-treatment-for-breast-cancer",
      "url": "https://finnhub.io/api/news?id=fedecfa5364cb25e68721b9b014ff56edf68dd64fca3dd8cfa9cb0e7734ab8e0"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Feb 24, 2026",
    "summary": "Companies In The Article Are: NVO,LLY,DASH,PYPL,VRE",
    "url": "https://finnhub.io/api/news?id=74408a27262a5d88f8c5f99fcca4896f92eebb59f7a3238f5edecfd460bb829e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771935720,
      "headline": "Company News for Feb 24, 2026",
      "id": 139197293,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies In The Article Are: NVO,LLY,DASH,PYPL,VRE",
      "url": "https://finnhub.io/api/news?id=74408a27262a5d88f8c5f99fcca4896f92eebb59f7a3238f5edecfd460bb829e"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors.",
    "summary": "Hims & Hers, the telehealth provider best known for its compounded weight-loss drugs, issues a weak outlook.",
    "url": "https://finnhub.io/api/news?id=a8e53acd5534f19d0b4909463573cb5b01e03399d6062c047c7d55dd53eee91e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771928940,
      "headline": "Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors.",
      "id": 139193505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers, the telehealth provider best known for its compounded weight-loss drugs, issues a weak outlook.",
      "url": "https://finnhub.io/api/news?id=a8e53acd5534f19d0b4909463573cb5b01e03399d6062c047c7d55dd53eee91e"
    }
  },
  {
    "ts": null,
    "headline": "Markets Must Look Past the AI Panic. Jamie Dimon Offers Some Hope.",
    "summary": "Waller calls March rate decision a coin flip, a viral online post slams stocks, tariff refunds are in play, and more news to start your day.",
    "url": "https://finnhub.io/api/news?id=6cba4b6d77ac21b7fb083a276a7c63338f212762a92c11042943b81ce7727d06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771933920,
      "headline": "Markets Must Look Past the AI Panic. Jamie Dimon Offers Some Hope.",
      "id": 139194331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Waller calls March rate decision a coin flip, a viral online post slams stocks, tariff refunds are in play, and more news to start your day.",
      "url": "https://finnhub.io/api/news?id=6cba4b6d77ac21b7fb083a276a7c63338f212762a92c11042943b81ce7727d06"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk, United Laboratories Say New Obesity Drug Helps Patients Lose Weight in Trial",
    "summary": "Novo Nordisk said an experimental obesity drug it is jointly developing with China’s United Laboratories International Holdings helped patients lose weight in a midstage clinical trial in China.",
    "url": "https://finnhub.io/api/news?id=ac309cbe42dda1240f549170b050fed84341533a53ac6f9b5e66f62f7f82fdd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771928520,
      "headline": "Novo Nordisk, United Laboratories Say New Obesity Drug Helps Patients Lose Weight in Trial",
      "id": 139193234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk said an experimental obesity drug it is jointly developing with China’s United Laboratories International Holdings helped patients lose weight in a midstage clinical trial in China.",
      "url": "https://finnhub.io/api/news?id=ac309cbe42dda1240f549170b050fed84341533a53ac6f9b5e66f62f7f82fdd6"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk selloff continues as stock gets hit with rating downgrades",
    "summary": "Investing.com -- JPMorgan downgraded Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to Neutral from Overweight after disappointing late-stage REDEFINE-4 results for its obesity drug CagriSema showed weaker-than-expected competitiveness versus Eli Lilly’s (NYSE:LLY) Zepbound.",
    "url": "https://finnhub.io/api/news?id=259c78226d871b45a7e04c278ad3c89347891f95e641499a317c1745c1734912",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771928380,
      "headline": "Novo Nordisk selloff continues as stock gets hit with rating downgrades",
      "id": 139193221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- JPMorgan downgraded Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to Neutral from Overweight after disappointing late-stage REDEFINE-4 results for its obesity drug CagriSema showed weaker-than-expected competitiveness versus Eli Lilly’s (NYSE:LLY) Zepbound.",
      "url": "https://finnhub.io/api/news?id=259c78226d871b45a7e04c278ad3c89347891f95e641499a317c1745c1734912"
    }
  },
  {
    "ts": null,
    "headline": "What could save the markets from AI Armageddon? Populist backlash — and it’s already started.",
    "summary": "What could save the markets from AI Armageddon? Populist backlash — and it’s already started.",
    "url": "https://finnhub.io/api/news?id=4ebb0ee3769108d94ed28f37669432646762bc57987cb0487b5ab42194e18007",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771926120,
      "headline": "What could save the markets from AI Armageddon? Populist backlash — and it’s already started.",
      "id": 139211412,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "What could save the markets from AI Armageddon? Populist backlash — and it’s already started.",
      "url": "https://finnhub.io/api/news?id=4ebb0ee3769108d94ed28f37669432646762bc57987cb0487b5ab42194e18007"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture",
    "summary": "Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture",
    "url": "https://finnhub.io/api/news?id=8bf16ef1b4fdae660e7047e0c602cf2098314e6b713f2505cb8891f2b6e2d99f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771923600,
      "headline": "Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture",
      "id": 139194879,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8bf16ef1b4fdae660e7047e0c602cf2098314e6b713f2505cb8891f2b6e2d99f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients",
    "summary": "The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or coinsurance benefit designs.",
    "url": "https://finnhub.io/api/news?id=43a83ca02a714a492b4971fac9d0ff55c62a610df8681a17b45c9b24e69f5d4e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771923255,
      "headline": "Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients",
      "id": 139198055,
      "image": "https://image.cnbcfm.com/api/v1/image/108261298-17702146372026-02-04t141023z_346821360_rc20fjakic3w_rtrmadp_0_novo-nordisk-results.jpeg?v=1770311641&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or coinsurance benefit designs. ",
      "url": "https://finnhub.io/api/news?id=43a83ca02a714a492b4971fac9d0ff55c62a610df8681a17b45c9b24e69f5d4e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy",
    "summary": "Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy",
    "url": "https://finnhub.io/api/news?id=02f8b46a74a3bcb3f8a50b0fceae624b566bf91cd356c758f2ad8c6183844c64",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771921560,
      "headline": "Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy",
      "id": 139211413,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy",
      "url": "https://finnhub.io/api/news?id=02f8b46a74a3bcb3f8a50b0fceae624b566bf91cd356c758f2ad8c6183844c64"
    }
  },
  {
    "ts": null,
    "headline": "Meta-AMD chip deal, Wall Street's AI angst, Trump's State of the Union and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=ad42f63535895093be5f42b88548dee63f7a533b33f695bbd170118e8771ed45",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771921207,
      "headline": "Meta-AMD chip deal, Wall Street's AI angst, Trump's State of the Union and more in Morning Squawk",
      "id": 139197919,
      "image": "https://image.cnbcfm.com/api/v1/image/108267883-1771600340652-gettyimages-2262113458-AFP_98CY9UB.jpeg?v=1771898197&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=ad42f63535895093be5f42b88548dee63f7a533b33f695bbd170118e8771ed45"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades",
    "summary": "Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.",
    "url": "https://finnhub.io/api/news?id=e540f521c0f0f19ff0e9e34d428e4f1023f1866904344869ab802ff1cbd8527b",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771919587,
      "headline": "Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades",
      "id": 139198057,
      "image": "https://image.cnbcfm.com/api/v1/image/108226743-1763385742494-gettyimages-2212016375-NOVO_WEGOVY.jpeg?v=1766491855&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.",
      "url": "https://finnhub.io/api/news?id=e540f521c0f0f19ff0e9e34d428e4f1023f1866904344869ab802ff1cbd8527b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight",
    "summary": "United Biotechnology and Novo Nordisk share positive results from Chinese phase 2 trial of UBT251 for weight loss.",
    "url": "https://finnhub.io/api/news?id=3eee888772b28964bfd96bea1aa20d8d06f880fa3a1b87114d6b15c6d0e029af",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771916430,
      "headline": "Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight",
      "id": 139194662,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/24/Novo-Nordisk.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "United Biotechnology and Novo Nordisk share positive results from Chinese phase 2 trial of UBT251 for weight loss.",
      "url": "https://finnhub.io/api/news?id=3eee888772b28964bfd96bea1aa20d8d06f880fa3a1b87114d6b15c6d0e029af"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock Underperforming the S&P 500?",
    "summary": "Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.",
    "url": "https://finnhub.io/api/news?id=0b2b70cec4b1794e1d2e5a9d35894e94252a85c64d3c170a9e31cfc6454adca3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771913096,
      "headline": "Is Eli Lilly Stock Underperforming the S&P 500?",
      "id": 139192431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.",
      "url": "https://finnhub.io/api/news?id=0b2b70cec4b1794e1d2e5a9d35894e94252a85c64d3c170a9e31cfc6454adca3"
    }
  },
  {
    "ts": null,
    "headline": "Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs",
    "summary": "By Maggie Fick and Bhanvi Satija LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it",
    "url": "https://finnhub.io/api/news?id=ef2675ed8a94f13d36d68c6dc93ccf6749cbaec8dd80953a9da169dca4f37c80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771909900,
      "headline": "Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs",
      "id": 139190947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By Maggie Fick and Bhanvi Satija LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it",
      "url": "https://finnhub.io/api/news?id=ef2675ed8a94f13d36d68c6dc93ccf6749cbaec8dd80953a9da169dca4f37c80"
    }
  },
  {
    "ts": null,
    "headline": "CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story",
    "summary": "Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly's tirzepatide in a head to head Phase 3 trial. The readout from this pivotal study challenges Novo Nordisk's efforts to strengthen its position in the competitive market for injectable weight loss therapies. The result introduces fresh questions around CagriSema's commercial potential and the company's roadmap for future obesity...",
    "url": "https://finnhub.io/api/news?id=da846c2821a3bab8750e068c78f7a8e356a42650a1cd1db06a74adc2be34ca27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771902773,
      "headline": "CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story",
      "id": 139190241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly's tirzepatide in a head to head Phase 3 trial. The readout from this pivotal study challenges Novo Nordisk's efforts to strengthen its position in the competitive market for injectable weight loss therapies. The result introduces fresh questions around CagriSema's commercial potential and the company's roadmap for future obesity...",
      "url": "https://finnhub.io/api/news?id=da846c2821a3bab8750e068c78f7a8e356a42650a1cd1db06a74adc2be34ca27"
    }
  },
  {
    "ts": null,
    "headline": "CNBC Daily Open: Unstable tariff situation and new AI disruption spark market sell-off",
    "summary": "Investors lost their sense of security in the business of cybersecurity companies after Anthropic on Friday launched an AI-powered security scanning tool.",
    "url": "https://finnhub.io/api/news?id=3fe00c4f095fce2986cc93bf04b1b2d6f635d2a5aeb406588da1133b2b103339",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771900070,
      "headline": "CNBC Daily Open: Unstable tariff situation and new AI disruption spark market sell-off",
      "id": 139198058,
      "image": "https://image.cnbcfm.com/api/v1/image/108268697-17718739192026-02-23t185310z_1431866267_rc2srjaiwe81_rtrmadp_0_usa-stocks.jpeg?v=1771873936&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Investors lost their sense of security in the business of cybersecurity companies after Anthropic on Friday launched an AI-powered security scanning tool.",
      "url": "https://finnhub.io/api/news?id=3fe00c4f095fce2986cc93bf04b1b2d6f635d2a5aeb406588da1133b2b103339"
    }
  },
  {
    "ts": null,
    "headline": "Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.",
    "summary": "Is this the best way to cash in on the weight-loss gold rush?",
    "url": "https://finnhub.io/api/news?id=b6d9ada71784254e3e59d11304e48f670fc5d4b1dca52f075f8bf3eb64ddc85e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771897800,
      "headline": "Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.",
      "id": 139189483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Is this the best way to cash in on the weight-loss gold rush?",
      "url": "https://finnhub.io/api/news?id=b6d9ada71784254e3e59d11304e48f670fc5d4b1dca52f075f8bf3eb64ddc85e"
    }
  }
]